Skip to main content

Retrospective Analysis of Prismaflex HF20 Set Versus ppCRRT Registry

Completed · NCT06633029

Conditions: Acute Renal Failure (ARF), Acute Kidney Injury (AKI), Fluid Overload in Dialysis Patients

At a glance

Research payments reported, 2025
$380,401
U.S. investigators named
6
Sites paid
6
Planned or actual enrollment
59

About the trial

Sponsor
Vantive Health LLC (with Baxter Healthcare Corporation)
Tested
Prismaflex HF20 (device)
Dates
Started 2024-12-11; completion 2025-06-25
Results posted
Not yet

A retrospective multicenter, observational design intended to capture data on pediatrics (weighing between 8 - 20 kg) who underwent continuous renal replacement therapy (CRRT) using the HF20 set. Data will be compared with a similar population (weighting 8-20 kg) from the ppCRRT registry who received CRRT with Prismaflex M60 sets.

From ClinicalTrials.gov, last updated 2026-02-17. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Vantive US Healthcare LLC reported $380,401 in research payments for this study in 2025 (27 payments).

Products named: Renal - Prismaflex Hf 20 Sets, Renal - Acute

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.